Sonny Wong, MD
Cardiovascular Disease · Kailua, HINPI 1457369571
Payments from drug & device makers
Across 483 payments — averaging $36.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$2K
- Abbott$2K
- Boston Scientific$2K
- AstraZeneca$1K
- Johnson & Johnson$1K
- Medtronic$957
- plus $8K from 31 others
What the payments were for
- Travel & lodging$3882%
- Food & beverage$17,13596%
- Education$2581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 19 | $2,153 |
| Abbott | 20 | $2,063 |
| Boston Scientific | 14 | $1,677 |
| AstraZeneca | 46 | $1,463 |
| Johnson & Johnson | 52 | $1,211 |
| Medtronic(2 entities) | 17 | $957 |
| Merck | 31 | $889 |
| Novartis | 47 | $782 |
| Amgen | 36 | $737 |
| Bayer | 27 | $659 |
| Impulse Dynamics (USA) Inc. | 3 | $530 |
| Amarin Pharma, Inc. | 21 | $446 |
| E.r. Squibb & Sons, L.L.C. | 21 | $432 |
| Esperion Therapeutics, Inc. | 20 | $383 |
| Shockwave Medical, Inc | 2 | $347 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $344 |
| Abiomed | 5 | $336 |
| Galderma Laboratories, L.p. | 10 | $319 |
| Biotronik Inc. | 5 | $305 |
| Pfizer | 13 | $241 |
| AbbVie(2 entities) | 4 | $222 |
| Philips North America LLC | 10 | $217 |
| Gilead | 14 | $189 |
| Irhythm Technologies, Inc. | 4 | $140 |
| Siemens Medical Solutions USA, Inc. | 1 | $118 |
| Kowa Pharmaceuticals America, Inc. | 6 | $110 |
| Sanofi-aventis U.S. LLC | 4 | $94 |
| Regeneron Healthcare Solutions, Inc. | 5 | $91 |
| Boehringer Ingelheim | 3 | $76 |
| Venclose Inc. | 1 | $66 |
| Scpharmaceuticals Inc. | 2 | $51 |
| Baxter Healthcare | 2 | $44 |
| Lilly USA, LLC | 1 | $19 |
| Medicomp Inc | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$891
- Watchman$581
- XARELTO$522
- Venclose Maven Catheter$425
- GENERAL VASCULAR INTERVENTION$422
- Confirm Rx$419
- FARXIGA$373
- VERQUVO$371
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$347
- AVEIR$311
- Micra$299
- MitraClip System$271
- ENSITE$177
- MitraClip$170
- JOT DX$154
- Varithena Administration Pack$134
- VenaSeal$129
- ENTRESTO$125
- Kerendia$125
- LOKELMA$122
How this compares
$17,781 in reported general payments places this provider in the 90th percentile of 73 cardiovascular disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 264 | $334,198 |
| XareltoRivaroxaban | 238 | $313,036 |
| EntrestoSacubitril/Valsartan | 121 | $188,279 |
| NexlizetBempedoic Acid/Ezetimibe | 69 | $61,744 |
| Repatha SureclickEvolocumab | 45 | $51,677 |
| FarxigaDapagliflozin Propanediol | 44 | $49,871 |
| JardianceEmpagliflozin | 23 | $38,036 |
| Repatha PushtronexEvolocumab | 17 | $15,880 |
| Rosuvastatin Calcium | 505 | $14,898 |
| BrilintaTicagrelor | 14 | $13,952 |
| Ezetimibe | 327 | $12,813 |
| VascepaIcosapent Ethyl | 14 | $12,780 |
| Atorvastatin Calcium | 461 | $11,308 |
| Metoprolol Succinate | 364 | $7,162 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 83 | $4,940 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $241 | $334,198264 claims |
| Johnson & JohnsonXarelto | $1,211 | $313,036238 claims |
| NovartisEntresto | $782 | $188,279121 claims |
| AstraZenecaFarxiga, Brilinta | $1,463 | $63,82358 claims |
| Esperion Therapeutics, Inc.Nexlizet | $383 | $61,74469 claims |
| Boehringer IngelheimJardiance | $76 | $38,03623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 73 cardiovascular disease providers in Hawaii.
Other cardiovascular disease in Kailua
- Ramy BadawiKailua$78K
- Michael YeeKailua$9K
- Dipanjan BanerjeeHonolulu$452K
- Ryan SmithKaneohe$125K
- Joana MagnoHonolulu$23K
- Hingson ChunHonolulu$23K
- William DangHonolulu$16K
- Erin DreessensTripler Amc$14K
- Edward ShenHonolulu$12K
- Se Kon WonHonolulu$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.